Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro

• Autor(a) principal: Zacharias, Patrícia
• Data de Publicação: 2017
• Outros Autores: Damião, Aderson Omar Mourão Cintra, Moraes, Antonio Carlos, Teixeira, Fábio Vieira, Ludvig, Juliano Coelho, Nones, Rodrigo Bremer, Saad-Hossne, Rogerio [UNESP], Sassaki, Ligia Yukie [UNESP], da Silva, Rosemary Pereira Lino [UNESP], Facchin, Luiza, Olandoski, Marcia, Kotze, Paulo Gustavo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/s0004-2803.201700000-51; http://hdl.handle.net/11449/179347
• topic: Adalimumab; Inflammatory bowel diseases; Proctocolitis; Ulcerative colitis

Background – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up.